Loading...
XNAS
EDAP
Market cap65mUSD
May 16, Last price  
1.76USD
1D
0.00%
1Q
-38.46%
Jan 2017
-46.34%
Name

Edap Tms SA

Chart & Performance

D1W1MN
P/E
P/S
0.92
EPS
Div Yield, %
Shrs. gr., 5y
4.71%
Rev. gr., 5y
7.38%
Revenues
64m
+6.11%
20,794,51020,265,17622,362,10523,053,00024,885,00023,708,00022,292,00026,065,00024,079,00026,785,00032,253,00035,611,00035,746,00039,182,00044,911,00041,662,00044,066,00055,109,00060,423,00064,115,000
Net income
-19m
L-10.20%
0001,597,000-7,766,000-12,717,000-938,000-7,475,000-5,021,000-512,000-1,667,0003,842,000-681,000-338,0001,512,000-1,704,000700,000-2,933,000-21,178,000-19,018,000
CFO
-14m
L-7.45%
000-4,593,000-3,664,000-3,818,000-737,000-162,000-2,495,000-1,014,0001,338,0001,119,000-3,059,000175,0003,800,0001,977,0004,445,000-3,024,000-14,678,000-13,584,000

Profile

EDAP TMS S.A., together with its subsidiaries, develops, produces, markets, distributes, and maintains a portfolio of minimally invasive medical devices for the treatment of urological diseases in Asia, France, the United States, and internationally. It operates in three segments: High Intensity Focused Ultrasound (HIFU), Extracorporeal ShockWave Lithotripsy (ESWL), and Distribution Services (DIST). The HIFU segment develops, manufactures, and markets medical devices based on HIFU technology for the minimally invasive treatment of urological and other clinical indications. This segment also offers Ablatherm, an ultrasound guided robotic HIFU device for the treatment of organ-confined prostate cancer; Ablatherm Fusion that incorporates the company's proprietary fusion software, which merges MRI and ultrasound images; and the Focal One, a HIFU robotic device dedicated to the focal therapy of prostate cancer, as well as disposables, and leasing and treatment related services; and maintenance services. The ESWL division manufactures, markets, and services lithotripter for the treatment of urinary tract stones by means of ESWL technology; and offers Sonolith i-move, an extracorporeal shockwave lithotripter to small and mid-size hospitals, as well as sells disposable parts for lithotripters and electrodes. The Distribution division markets, distributes, and services lasers, micro-ultrasound systems, and other medical products from third parties, as well as leases devices; sells disposables and spare parts; and offers maintenance services. The company markets and sells its products through its direct marketing, sales organization, and service platform, as well as through third-party distributors and agents. Its customers include hospitals, urology clinics, and research institutions. The company was incorporated in 1979 and is headquartered in Lyon, France.
IPO date
Aug 01, 1997
Employees
264
Domiciled in
FR
Incorporated in
FR

Valuation

Title
EUR in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
64,115
6.11%
60,423
9.64%
55,109
25.06%
Cost of revenue
84,649
80,235
59,367
Unusual Expense (Income)
NOPBT
(20,534)
(19,812)
(4,258)
NOPBT Margin
Operating Taxes
289
644
837
Tax Rate
NOPAT
(20,823)
(20,456)
(5,095)
Net income
(19,018)
-10.20%
(21,178)
622.06%
(2,933)
-519.00%
Dividends
Dividend yield
Proceeds from repurchase of equity
256
21,960
BB yield
-0.13%
-5.99%
Debt
Debt current
9,819
5,112
1,846
Long-term debt
7,207
5,720
6,031
Deferred revenue
358
264
Other long-term liabilities
2,897
3,717
2,710
Net debt
(12,810)
(32,639)
(55,259)
Cash flow
Cash from operating activities
(13,584)
(14,678)
(3,024)
CAPEX
(1,315)
(3,762)
(2,183)
Cash from investing activities
(4,120)
(4,344)
(2,378)
Cash from financing activities
4,635
(911)
21,741
FCF
(22,403)
(27,747)
(9,264)
Balance
Cash
29,836
43,471
63,136
Long term investments
Excess cash
26,630
40,450
60,381
Stockholders' equity
(82,573)
(63,185)
(41,425)
Invested Capital
140,644
132,249
122,467
ROIC
ROCE
EV
Common stock shares outstanding
37,286
36,997
34,393
Price
2.21
-58.14%
5.28
-50.47%
10.66
77.96%
Market cap
82,403
-57.82%
195,343
-46.72%
366,625
88.77%
EV
69,593
162,704
311,366
EBITDA
(17,969)
(17,899)
(2,653)
EV/EBITDA
Interest
236
232
168
Interest/NOPBT